Metabolomic/lipidomic profiling of COVID-19 and individual response to tocilizumab
Gaia Meoni, Veronica Ghini, Laura Maggi, Alessia Vignoli, Alessio Mazzoni, Lorenzo Salvati, Manuela Capone, Anna Vanni, Leonardo Tenori, Paolo Fontanari, Federico Lavorini, Adriano Peris, Alessandro Bartoloni, Francesco Liotta, Lorenzo Cosmi, Claudio Luchinat, Francesco Annunziato, Paola Turano
doi: https://doi.org/10.1101/2020.11.10.20228361
Gaia Meoni
aMagnetic Resonance Center (CERM), University of Florence, 50019, Sesto Fiorentino, FI, Italy
bGiotto Biotech srl, 50019, Sesto Fiorentino, FI, Italy
Veronica Ghini
aMagnetic Resonance Center (CERM), University of Florence, 50019, Sesto Fiorentino, FI, Italy
cConsorzio Interuniversitario Risonanze Magnetiche di Metallo Proteine (CIRMMP), University of Florence, 50019, Sesto Fiorentino, FI, Italy
Laura Maggi
dDepartment of Clinical and Experimental Medicine, University of Florence, 50134, FI, Italy
Alessia Vignoli
aMagnetic Resonance Center (CERM), University of Florence, 50019, Sesto Fiorentino, FI, Italy
cConsorzio Interuniversitario Risonanze Magnetiche di Metallo Proteine (CIRMMP), University of Florence, 50019, Sesto Fiorentino, FI, Italy
Alessio Mazzoni
dDepartment of Clinical and Experimental Medicine, University of Florence, 50134, FI, Italy
Lorenzo Salvati
dDepartment of Clinical and Experimental Medicine, University of Florence, 50134, FI, Italy
Manuela Capone
dDepartment of Clinical and Experimental Medicine, University of Florence, 50134, FI, Italy
Anna Vanni
dDepartment of Clinical and Experimental Medicine, University of Florence, 50134, FI, Italy
Leonardo Tenori
aMagnetic Resonance Center (CERM), University of Florence, 50019, Sesto Fiorentino, FI, Italy
eDepartment of Chemistry “Ugo Schiff”, University of Florence,50019 Sesto Fiorentino, FI, Italy
Paolo Fontanari
fCardiac Anaesthesia and Intensive Care Unit, Careggi University Hospital, 50134, FI, Italy
Federico Lavorini
dDepartment of Clinical and Experimental Medicine, University of Florence, 50134, FI, Italy
gPneumology and Intensive Care Unit, Careggi University Hospital, 50134, FI, Italy
Adriano Peris
hIntensive Care Unit and Regional ECMO Referral Centre, Careggi University Hospital, 50134, FI, Italy
Alessandro Bartoloni
dDepartment of Clinical and Experimental Medicine, University of Florence, 50134, FI, Italy
iInfectious and Tropical Diseases Unit, Careggi University Hospital, 50134, FI, Italy
Francesco Liotta
dDepartment of Clinical and Experimental Medicine, University of Florence, 50134, FI, Italy
jImmunology and Cell Therapy Unit, Careggi University Hospital, 50134, FI, Italy
Lorenzo Cosmi
dDepartment of Clinical and Experimental Medicine, University of Florence, 50134, FI, Italy
jImmunology and Cell Therapy Unit, Careggi University Hospital, 50134, FI, Italy
Claudio Luchinat
aMagnetic Resonance Center (CERM), University of Florence, 50019, Sesto Fiorentino, FI, Italy
eDepartment of Chemistry “Ugo Schiff”, University of Florence,50019 Sesto Fiorentino, FI, Italy
Francesco Annunziato
dDepartment of Clinical and Experimental Medicine, University of Florence, 50134, FI, Italy
kFlow Cytometry Diagnostic Center and Immunoterapy (CDCI), Careggi University Hospital, 50134, FI, Italy
Paola Turano
dDepartment of Clinical and Experimental Medicine, University of Florence, 50134, FI, Italy
eDepartment of Chemistry “Ugo Schiff”, University of Florence,50019 Sesto Fiorentino, FI, Italy
Data Availability
All the NMR files will be available from the MetaboLights database after publication.
Posted November 13, 2020.
Metabolomic/lipidomic profiling of COVID-19 and individual response to tocilizumab
Gaia Meoni, Veronica Ghini, Laura Maggi, Alessia Vignoli, Alessio Mazzoni, Lorenzo Salvati, Manuela Capone, Anna Vanni, Leonardo Tenori, Paolo Fontanari, Federico Lavorini, Adriano Peris, Alessandro Bartoloni, Francesco Liotta, Lorenzo Cosmi, Claudio Luchinat, Francesco Annunziato, Paola Turano
medRxiv 2020.11.10.20228361; doi: https://doi.org/10.1101/2020.11.10.20228361
Metabolomic/lipidomic profiling of COVID-19 and individual response to tocilizumab
Gaia Meoni, Veronica Ghini, Laura Maggi, Alessia Vignoli, Alessio Mazzoni, Lorenzo Salvati, Manuela Capone, Anna Vanni, Leonardo Tenori, Paolo Fontanari, Federico Lavorini, Adriano Peris, Alessandro Bartoloni, Francesco Liotta, Lorenzo Cosmi, Claudio Luchinat, Francesco Annunziato, Paola Turano
medRxiv 2020.11.10.20228361; doi: https://doi.org/10.1101/2020.11.10.20228361
Subject Area
Subject Areas
- Addiction Medicine (368)
- Allergy and Immunology (689)
- Anesthesia (184)
- Cardiovascular Medicine (2744)
- Dermatology (234)
- Emergency Medicine (414)
- Epidemiology (12392)
- Forensic Medicine (10)
- Gastroenterology (784)
- Genetic and Genomic Medicine (4256)
- Geriatric Medicine (394)
- Health Economics (699)
- Health Informatics (2752)
- Health Policy (1018)
- Hematology (369)
- HIV/AIDS (879)
- Medical Education (404)
- Medical Ethics (111)
- Nephrology (451)
- Neurology (4032)
- Nursing (216)
- Nutrition (598)
- Oncology (2125)
- Ophthalmology (604)
- Orthopedics (251)
- Otolaryngology (312)
- Pain Medicine (256)
- Palliative Medicine (77)
- Pathology (478)
- Pediatrics (1147)
- Primary Care Research (466)
- Public and Global Health (6647)
- Radiology and Imaging (1446)
- Respiratory Medicine (886)
- Rheumatology (420)
- Sports Medicine (352)
- Surgery (464)
- Toxicology (57)
- Transplantation (192)
- Urology (171)